RU94028653A - Фармацевтический препарат - Google Patents

Фармацевтический препарат

Info

Publication number
RU94028653A
RU94028653A RU94028653/14A RU94028653A RU94028653A RU 94028653 A RU94028653 A RU 94028653A RU 94028653/14 A RU94028653/14 A RU 94028653/14A RU 94028653 A RU94028653 A RU 94028653A RU 94028653 A RU94028653 A RU 94028653A
Authority
RU
Russia
Prior art keywords
pharmaceutical preparation
inhibitor
preparation
glucosidase
biologically active
Prior art date
Application number
RU94028653/14A
Other languages
English (en)
Other versions
RU2141844C1 (ru
Inventor
Бремер Клаус-Дитер
Ch]
Савлевич Павел
Original Assignee
Ф.Хоффманн-Ля Рош Аг (Ch)
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)
Publication of RU94028653A publication Critical patent/RU94028653A/ru
Application granted granted Critical
Publication of RU2141844C1 publication Critical patent/RU2141844C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Фармацевтический препарат, содержащий в качестве биологически активных веществ ингибитор глюкозидазы и/или амилазы и ингибитор липазы и обычные фармацевтические наполнители.

Claims (1)

  1. Фармацевтический препарат, содержащий в качестве биологически активных веществ ингибитор глюкозидазы и/или амилазы и ингибитор липазы и обычные фармацевтические наполнители.
RU94028653A 1993-08-05 1994-08-05 Фармацевтическое соединение RU2141844C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH233993 1993-08-05
CH2339/93 1993-08-05

Publications (2)

Publication Number Publication Date
RU94028653A true RU94028653A (ru) 1996-09-10
RU2141844C1 RU2141844C1 (ru) 1999-11-27

Family

ID=4231504

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94028653A RU2141844C1 (ru) 1993-08-05 1994-08-05 Фармацевтическое соединение

Country Status (24)

Country Link
US (1) US5643874A (ru)
EP (1) EP0638317B1 (ru)
JP (1) JP2780932B2 (ru)
KR (1) KR100342285B1 (ru)
CN (1) CN1076196C (ru)
AT (1) ATE190503T1 (ru)
AU (1) AU684793B2 (ru)
BR (1) BR9403170A (ru)
CA (1) CA2128044C (ru)
CZ (1) CZ286202B6 (ru)
DE (1) DE59409200D1 (ru)
DK (1) DK0638317T3 (ru)
ES (1) ES2144019T3 (ru)
GR (1) GR3033643T3 (ru)
HU (1) HU222346B1 (ru)
IL (1) IL110510A (ru)
NO (1) NO313490B1 (ru)
NZ (1) NZ264142A (ru)
PL (1) PL175997B1 (ru)
PT (1) PT638317E (ru)
RU (1) RU2141844C1 (ru)
SA (1) SA94150156B1 (ru)
TW (1) TW381025B (ru)
ZA (1) ZA945673B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2207861C2 (ru) * 1998-01-09 2003-07-10 Гелтекс Фармасьютикалз, Инк. Полимеры, ингибирующие липазу

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1017408T3 (da) * 1997-02-05 2005-08-01 Hoffmann La Roche Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
NZ510311A (en) * 1998-09-08 2003-08-29 Smithkline Beecham Corp Lipstatin derivative - soluble fiber tablets
US6340669B1 (en) 1999-01-22 2002-01-22 Hunza Di Maria Carmela Marazzita S.A.S. Lipoprotein complexes and compositions containing them
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
US6342519B2 (en) * 1999-10-29 2002-01-29 2 Pro Chemical Oxetanone derivatives
US6348492B1 (en) * 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
CA2358921A1 (en) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
KR100349334B1 (ko) * 1999-12-08 2002-08-21 박관화 아카비오신 글루코실 시몬진 및 그것의 제조방법.
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
EP1307263B1 (en) 2000-07-28 2005-04-20 F. Hoffmann-La Roche Ag New use of lipase inhibitors
SI1307264T1 (en) * 2000-07-28 2005-02-28 F. Hoffmann-La Roche Ag New pharmaceutical composition
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
IL162323A0 (en) 2001-12-04 2005-11-20 Biogal Pharmaceutical Co Preparation of orlistat and orlistat crystalline forms
US7108869B2 (en) * 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
AU2005239788A1 (en) 2004-05-10 2005-11-17 University Of Copenhagen Flaxseeds for body weight management
US20060029567A1 (en) 2004-08-04 2006-02-09 Bki Holding Corporation Material for odor control
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
WO2006119038A1 (en) * 2005-04-29 2006-11-09 Naturegen, Inc. Compositions and methods for controlling glucose uptake
PL1897558T3 (pl) * 2005-06-09 2014-01-31 Norgine Bv Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2007219236B2 (en) * 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
JP2010509392A (ja) 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
JP2010510201A (ja) * 2006-11-20 2010-04-02 グレンマーク・ファーマシューティカルズ・エスエー ステアリン酸ＣｏＡ脱飽和酵素阻害剤としてのアセチレン誘導体
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
PL2002825T3 (pl) * 2007-06-14 2013-12-31 Krka Kompozycje farmaceutyczne zawierające orlistat
US9066536B2 (en) 2007-09-12 2015-06-30 University Of Copenhagen Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
RU2010128543A (ru) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
DK2326638T5 (da) * 2008-08-06 2014-01-13 Pfizer Ltd Diazepin- og diazocan-forbindelser som mc4-agonister
JP5752359B2 (ja) * 2010-02-25 2015-07-22 富士フイルム株式会社 体重増加抑制組成物及びこれを含む食品
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
WO2013133685A1 (en) 2012-03-09 2013-09-12 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
JP2016510306A (ja) * 2012-05-08 2016-04-07 セリックスビオ プライヴェート リミテッド 高血糖の治療のための組成物及び方法
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
BR112017012714B1 (pt) 2014-12-17 2023-09-26 Empros Pharma Ab Composição de liberação modificada
KR101903150B1 (ko) 2016-09-12 2018-10-01 가톨릭대학교산학협력단 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FI844289L (fi) * 1984-01-21 1985-07-22 Hoechst Ag Nya polypeptider med -amylashaemmande verkan, foerfarande foer deras framstaellning, deras anvaendning och farmaceutiska preparat.
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
CA1329127C (en) * 1988-08-22 1994-05-03 Takao Matsuo Calcium absorption promoter
DK244090D0 (da) * 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2207861C2 (ru) * 1998-01-09 2003-07-10 Гелтекс Фармасьютикалз, Инк. Полимеры, ингибирующие липазу

Also Published As

Publication number Publication date
CZ182594A3 (en) 1995-02-15
DE59409200D1 (de) 2000-04-20
HU9402249D0 (en) 1994-09-28
EP0638317B1 (de) 2000-03-15
SA94150156B1 (ar) 2005-05-15
NO313490B1 (no) 2002-10-14
RU2141844C1 (ru) 1999-11-27
CA2128044A1 (en) 1995-02-06
CN1106701A (zh) 1995-08-16
CA2128044C (en) 2007-02-20
NO942900D0 (ru) 1994-08-04
TW381025B (en) 2000-02-01
AU6883994A (en) 1995-02-16
IL110510A (en) 1999-03-12
DK0638317T3 (da) 2000-06-26
CZ286202B6 (cs) 2000-02-16
KR950005319A (ko) 1995-03-20
JPH0753409A (ja) 1995-02-28
IL110510A0 (en) 1994-11-11
EP0638317A1 (de) 1995-02-15
KR100342285B1 (ko) 2002-10-25
NO942900L (no) 1995-02-06
PL304557A1 (en) 1995-02-06
PL175997B1 (pl) 1999-03-31
ATE190503T1 (de) 2000-04-15
JP2780932B2 (ja) 1998-07-30
CN1076196C (zh) 2001-12-19
HUT68300A (en) 1995-06-28
ZA945673B (en) 1995-02-07
HU222346B1 (hu) 2003-06-28
BR9403170A (pt) 1995-04-18
AU684793B2 (en) 1998-01-08
ES2144019T3 (es) 2000-06-01
NZ264142A (en) 1996-11-26
US5643874A (en) 1997-07-01
GR3033643T3 (en) 2000-10-31
PT638317E (pt) 2000-07-31

Similar Documents

Publication Publication Date Title
RU94028653A (ru) Фармацевтический препарат
RU94046294A (ru) Стероидные гликозиды для лечения гиперхолестеринэмии
AU4718496A (en) Use of aerogels in agriculture
RU95101387A (ru) Концентрированный водный раствор аргатробана
RU95114376A (ru) Нитроэфиры, обладающие фармакологической активностью, и способ их получения
CA2136331A1 (en) New pharmaceutical uses of krill enzymes
ATE316794T1 (de) Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
RU95106674A (ru) Полиеновые соединения, фармацевтическая и косметическая композиция на их основе
BR9606674B1 (pt) novo derivado de composto de antraciclina e preparação farmacêutica contendo o mesmo.
AU6633596A (en) Improved therapeutic agents
RU95101041A (ru) Липосомные растворы
FR2752422B1 (fr) Composition pharmaceutique contenant des acides 4-oxo-butanoiques
EA199800573A1 (ru) Таблетки с высоким содержанием фамцикловира
FR2754824B1 (fr) Nouvelle composition contenant du chitosan
FI964448A0 (fi) Uusi biologisesti aktiivinen peptidi ja sen valmistus
AU5994796A (en) Modified kojibiosides analogues
RU94028126A (ru) Средство, обладающее иммуномодулирующей активностью
RU94036666A (ru) Биостимулирующее средство
FR2715564B1 (fr) Composition pharmaceutique contenant de la N-acétyl-cystéine.
EP0462291A4 (en) Acat enzyme inhibiting composition
AU6309198A (en) Drugs containing enzyme inhibitors as active ingredients
RU94036667A (ru) Биоэнергомодулятор
NO991047L (no) Transdermal terapeutisk tilnµrming involverende en kombinasjon av aktive substanser inneholdende °striol
DE69834434D1 (de) Verbindung und Arzneizusammensetzung zur Verabreichung von Wirkstoffen
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen